Document Detail


JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
MedLine Citation:
PMID:  22712764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M in EGFR and amplification of the MET gene account for this resistance; however, the mechanism(s) of approximately 30% of acquired resistance cases remain unknown. We established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. It was found in the present study that 3-12 h of exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft model. Our results suggest that the activation of JAK2 partially accounts for acquired erlotinib resistance.
Authors:
Daijiro Harada; Nagio Takigawa; Nobuaki Ochi; Takashi Ninomiya; Masayuki Yasugi; Toshio Kubo; Hiromasa Takeda; Eiki Ichihara; Kadoaki Ohashi; Saburo Takata; Mitsune Tanimoto; Katsuyuki Kiura
Related Documents :
22791394 - A role for c-abl in cell senescence and spontaneous immortalization.
11133244 - Analysis of cell vibration for assessing axonemal motility in chlamydomonas.
15326184 - Crk associates with erm proteins and promotes cell motility toward hyaluronic acid.
20171364 - Expression of the inflammatory marker cyclooxygenase-2 in dental pulp cells cultured wi...
7835754 - Reduction of lipid-soluble nitroxides in cho cells and macrophage tumor cells.
21244744 - Biocompatibility of electrospun halloysite nanotube-doped poly(lactic-co-glycolic acid)...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-24
Journal Detail:
Title:  Cancer science     Volume:  103     ISSN:  1349-7006     ISO Abbreviation:  Cancer Sci.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-09     Completed Date:  2012-12-10     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101168776     Medline TA:  Cancer Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  1795-802     Citation Subset:  IM    
Copyright Information:
© 2012 Japanese Cancer Association.
Affiliation:
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / genetics,  metabolism*
Animals
Blotting, Western
Cell Line, Tumor
Drug Resistance, Neoplasm / genetics*
Enzyme Activation / drug effects
Female
Gene Knockdown Techniques
Genes, erbB-1
Humans
Janus Kinase 2 / metabolism*
Lung Neoplasms / genetics,  metabolism*
Mice
Mice, Nude
Mutation*
Protein Kinase Inhibitors / pharmacology*
Quinazolines / pharmacology*
Signal Transduction / drug effects,  physiology*
Xenograft Model Antitumor Assays
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; EC 2.7.10.2/JAK2 protein, human; EC 2.7.10.2/Janus Kinase 2; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and characterization of solvent-filled channels in human ferrochelatase.
Next Document:  PLLA Microalloys Vs. PLLA Nanoalloys: Preparation, Morphologies and Properties.